Cumberland Pharmaceuticals Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Cumberland Pharmaceuticals Inc. (CPIX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $438.31 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-09
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $0.00.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $438.31K, a 242.33% increase from fiscal 2024.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $128.04K, a 88.95% decline from fiscal 2023.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.16M, a 74.77% decline from fiscal 2022.
- Cumberland Pharmaceuticals Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $4.59M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $438.31K 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $128.04K 10-K · filed 2026-03-09 | |||
| 2023-12-31 | $1.16M 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $4.59M 10-K · filed 2024-03-13 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-13 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $0.00 derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $3.63M 10-K · filed 2022-03-11 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $3.63M 10-Q · filed 2019-11-13 | $3.63M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $3.63M 10-Q · filed 2019-08-14 | $3.63M derived: sum of 3 quarters · filed 2021-03-12 | $3.63M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $3.63M 10-Q · filed 2020-05-22 | $3.63M derived: sum of 2 quarters · filed 2021-03-12 | $3.63M derived: sum of 3 quarters · filed 2021-03-12 | $3.63M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $0.00 derived: sum of 2 quarters · filed 2021-03-12 | $0.00 derived: sum of 3 quarters · filed 2021-03-12 | $0.00 10-K · filed 2021-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |